{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T13:35:07Z","timestamp":1792762507004,"version":"4.5.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,5]],"date-time":"2021-01-05T00:00:00Z","timestamp":1609804800000},"content-version":"vor","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000900","name":"Joint Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000900","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Chromatography A"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.chroma.2020.461767","type":"journal-article","created":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T11:33:24Z","timestamp":1606476804000},"page":"461767","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":94,"special_numbering":"C","title":["Asymmetric-flow field-flow fractionation for measuring particle size, drug loading and (in)stability of nanopharmaceuticals. The joint view of European Union Nanomedicine Characterization Laboratory and National Cancer Institute - Nanotechnology Characterization Laboratory"],"prefix":"10.1016","volume":"1635","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3235-2767","authenticated-orcid":false,"given":"F.","family":"Caputo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Mehn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.D.","family":"Clogston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"R\u00f6sslein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Prina-Mello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6222-9252","authenticated-orcid":false,"given":"S.E.","family":"Borgos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Gioria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Calzolai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.chroma.2020.461767_bib0001","unstructured":"https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/reflection-paper-surface-coatings-general-issues-consideration-regarding-parenteral-administration_en.pdf (accessed July 18, 2020)."},{"key":"10.1016\/j.chroma.2020.461767_bib0002","unstructured":"Liposome Drug Products: Chemistry, Manufacturing, and Controls; Human Pharmacokinetics and Bioavailability; and Labeling Documentation, https:\/\/www.fda.gov\/media\/70837\/download (accessed July 18, 2020)."},{"key":"10.1016\/j.chroma.2020.461767_bib0003","unstructured":"https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/joint-mhlw\/ema-reflection-paper-development-block-copolymer-micelle-medicinal-products_en.pdf (accessed July 18, 2020)."},{"key":"10.1016\/j.chroma.2020.461767_bib0004","unstructured":"https:\/\/www.ema.europa.eu\/en\/data-requirements-intravenous-liposomal-products-developed-reference-innovator-liposomal-product (accessed July 18, 2020)."},{"key":"10.1016\/j.chroma.2020.461767_bib0005","unstructured":"EMA Regulatory Science to 2025, https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/ema-regulatory-science-2025-strategic-reflection_en.pdf (accessed July 18, 2020)"},{"key":"10.1016\/j.chroma.2020.461767_bib0006","unstructured":"A. FDA\/CDER, \u201cDrug Products, Including Biological Products, that Contain Nanomaterials - Guidance for Industry, (2017). https:\/\/www.fda.gov\/media\/109910\/download (accessed July 18, 2020)."},{"key":"10.1016\/j.chroma.2020.461767_bib0007","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/jin2.34","article-title":"Identification of regulatory needs for nanomedicines","volume":"3","author":"Bremer-Hoffmann","year":"2018","journal-title":"Journal of Interdisciplinary Nanomedicine"},{"key":"10.1016\/j.chroma.2020.461767_bib0008","doi-asserted-by":"crossref","first-page":"e1531","DOI":"10.1002\/wnan.1531","article-title":"Mapping of the available standards against the regulatory needs for nanomedicines","volume":"11","author":"Halamoda-Kenzaoui","year":"2019","journal-title":"WIREs Nanomedicine and Nanobiotechnology"},{"key":"10.1016\/j.chroma.2020.461767_bib0009","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1021\/acs.molpharmaceut.8b01033","article-title":"Measuring Particle Size Distribution by Asymmetric Flow Field Flow Fractionation: A Powerful Method for the Preclinical Characterization of Lipid-Based Nanoparticles","volume":"16","author":"Caputo","year":"2019","journal-title":"Mol. Pharmaceutics."},{"key":"10.1016\/j.chroma.2020.461767_bib0010","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s11095-019-2736-y","article-title":"Sizing up the Next Generation of Nanomedicines","volume":"37","author":"Clogston","year":"2020","journal-title":"Pharm Res"},{"key":"10.1016\/j.chroma.2020.461767_bib0011","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s00216-019-02252-9","article-title":"The utility of asymmetric flow field-flow fractionation for preclinical characterization of nanomedicines","volume":"412","author":"Hu","year":"2020","journal-title":"Anal Bioanal Chem"},{"key":"10.1016\/j.chroma.2020.461767_bib0012","doi-asserted-by":"crossref","first-page":"5201","DOI":"10.1021\/ac501664t","article-title":"Asymmetric Flow Field-Flow Fractionation in the Field of Nanomedicine","volume":"86","author":"Wagner","year":"2014","journal-title":"Anal. Chem."},{"key":"10.1016\/j.chroma.2020.461767_bib0013","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jconrel.2019.02.030","article-title":"Measuring particle size distribution of nanoparticle enabled medicinal products, the joint view of EUNCL and NCI-NCL. A step by step approach combining orthogonal measurements with increasing complexity","volume":"299","author":"Caputo","year":"2019","journal-title":"Journal of Controlled Release."},{"key":"10.1016\/j.chroma.2020.461767_bib0014","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.aca.2013.11.021","article-title":"Rational strategy for characterization of nanoscale particles by asymmetric-flow field flow fractionation: A tutorial","volume":"809","author":"Gigault","year":"2014","journal-title":"Analytica Chimica Acta"},{"key":"10.1016\/j.chroma.2020.461767_bib0015","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jpba.2013.08.018","article-title":"Flow field-flow fractionation for the analysis of nanoparticles used in drug delivery","volume":"87","author":"Zattoni","year":"2014","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.chroma.2020.461767_bib0016","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1007\/s00216-017-0180-6","article-title":"Field flow fractionation techniques to explore the \u201cnano-world,\u201d","volume":"409","author":"Contado","year":"2017","journal-title":"Anal Bioanal Chem."},{"key":"10.1016\/j.chroma.2020.461767_bib0017","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.jconrel.2020.01.049","article-title":"Physical characterization of liposomal drug formulations using multi-detector asymmetrical-flow field flow fractionation","volume":"320","author":"Parot","year":"2020","journal-title":"Journal of Controlled Release"},{"key":"10.1016\/j.chroma.2020.461767_bib0018","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1002\/jssc.201200143","article-title":"Analysis of liposomes using asymmetrical flow field-flow fractionation: Separation conditions and drug\/lipid recovery: Other Techniques","volume":"35","author":"Kuntsche","year":"2012","journal-title":"J. Sep. Science."},{"key":"10.1016\/j.chroma.2020.461767_bib0019","doi-asserted-by":"crossref","first-page":"7827","DOI":"10.1007\/s00216-014-7643-9","article-title":"Asymmetrical flow field-flow fractionation with on-line detection for drug transfer studies: a feasibility study","volume":"406","author":"Hinna","year":"2014","journal-title":"Anal Bioanal Chem"},{"key":"10.1016\/j.chroma.2020.461767_bib0020","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.chemphyslip.2009.10.009","article-title":"Liposome fractionation and size analysis by asymmetrical flow field-flow fractionation\/multi-angle light scattering: influence of ionic strength and osmotic pressure of the carrier liquid","volume":"163","author":"Hupfeld","year":"2010","journal-title":"Chemistry and Physics of Lipids"},{"key":"10.1016\/j.chroma.2020.461767_bib0021","doi-asserted-by":"crossref","first-page":"555","DOI":"10.3390\/microorganisms7110555","article-title":"Asymmetrical Flow Field-Flow Fractionation on Virus and Virus-Like Particle Applications","volume":"7","author":"Eskelin","year":"2019","journal-title":"Microorganisms"},{"key":"10.1016\/j.chroma.2020.461767_bib0022","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1038\/s41596-019-0126-x","article-title":"Asymmetric-flow field-flow fractionation technology for exomere and small extracellular vesicle separation and characterization","volume":"14","author":"Zhang","year":"2019","journal-title":"Nature Protocols"},{"key":"10.1016\/j.chroma.2020.461767_bib0023","doi-asserted-by":"crossref","first-page":"539","DOI":"10.2217\/nnm-2017-0338","article-title":"Are existing standard methods suitable for the evaluation of nanomedicines: some case studies","volume":"13","author":"Gioria","year":"2018","journal-title":"Nanomedicine"},{"key":"10.1016\/j.chroma.2020.461767_bib0024","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1021\/ma60077a045","article-title":"Information on Polydispersity and Branching from Combined Quasi-Elastic and Intergrated Scattering","volume":"13","author":"Burchard","year":"1980","journal-title":"Macromolecules"},{"key":"10.1016\/j.chroma.2020.461767_bib0025","unstructured":"ISO TS 21362:2018, Nanotechnologies \u2014 Analysis of nano-objects using asymmetrical-flow and centrifugal field-flow fractionation."},{"key":"10.1016\/j.chroma.2020.461767_bib0026","unstructured":"http:\/\/www.euncl.eu\/about-us\/assay-cascade\/PDFs\/PCC\/EUNCL-PCC-022.pdf?m=1468937868&, (accessed July 18, 2020)."},{"key":"10.1016\/j.chroma.2020.461767_bib0027","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1039\/c2ib20117h","article-title":"Common pitfalls in nanotechnology: lessons learned from NCI's Nanotechnology Characterization Laboratory","volume":"5","author":"Crist","year":"2013","journal-title":"Integrative Biology"},{"key":"10.1016\/j.chroma.2020.461767_bib0028","first-page":"28","article-title":"Importance of Physicochemical Characterization Prior to Immunological Studies","author":"Clogston","year":"2010","journal-title":"Handbook of Immunological Properties of Engineered Nanomaterials"},{"key":"10.1016\/j.chroma.2020.461767_bib0029","series-title":"Polymer Nanoparticles for Nanomedicines","first-page":"187","article-title":"Physicochemical Characterization of Polymer Nanoparticles: Challenges and Present Limitations","author":"Clogston","year":"2016"},{"key":"10.1016\/j.chroma.2020.461767_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2020.07.007","article-title":"Delivering the power of nanomedicine to patients today","author":"Germain","year":"2020","journal-title":"Journal of Controlled Release"},{"key":"10.1016\/j.chroma.2020.461767_bib0031","doi-asserted-by":"crossref","unstructured":"B. Halamoda-Kenzaoui, H. Box, M. van Elk, S. Gaitan, R.E. Geertsma, E. Gainza Lafuente, A. Owen, A. Del Pozo, M. Roesslein, S. Bremer-Hoffmann, European Commission, Joint Research Centre, Anticipation of regulatory needs for nanotechnology-enabled health products: the REFINE white paper., 2019. https:\/\/op.europa.eu\/publication\/manifestation_identifier\/PUB_KJNA29919ENN (accessed July 18, 2020).","DOI":"10.33218\/001c.13521"},{"key":"10.1016\/j.chroma.2020.461767_bib0032","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1146\/annurev-anchem-091619-102216","article-title":"Emerging Standards and Analytical Science for Nanoenabled Medical Products","volume":"13","author":"Nelson","year":"2020","journal-title":"Annual Rev. Anal. Chem."},{"key":"10.1016\/j.chroma.2020.461767_bib0033","unstructured":"http:\/\/www.euncl.eu\/about-us\/assay-cascade\/PDFs\/PCC\/EUNCL_PCC_023.pdf?m=1526712237& , (acessed July 18, 2020)"},{"key":"10.1016\/j.chroma.2020.461767_bib0034","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S1773-2247(14)50002-0","article-title":"Nanotechnologies in Drug Delivery - An Industrial Perspective","volume":"24","author":"Bazile","year":"2014","journal-title":"Journal of Drug Delivery Science and Technology"},{"key":"10.1016\/j.chroma.2020.461767_bib0035","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s11051-020-04843-5","article-title":"Analytical ultracentrifugation for measuring drug distribution of doxorubicin loaded liposomes in human serum","volume":"22","author":"Mehn","year":"2020","journal-title":"J Nanopart Res"},{"key":"10.1016\/j.chroma.2020.461767_bib0036","doi-asserted-by":"crossref","unstructured":"Analytical ultracentrifugation for analysis of doxorubicin loaded liposomes | Elsevier Enhanced Reader, (n.d.). https:\/\/doi.org\/10.1016\/j.ijpharm.2017.03.046.","DOI":"10.1016\/j.ijpharm.2017.03.046"},{"key":"10.1016\/j.chroma.2020.461767_bib0037","doi-asserted-by":"crossref","unstructured":"Rapid Distribution of Liposomal Short-Chain Ceramide in Vitro and in Vivo | Drug Metabolism & Disposition, (n.d.). http:\/\/dmd.aspetjournals.org\/content\/36\/8\/1709 (accessed July 18, 2020).","DOI":"10.1124\/dmd.107.019679"},{"key":"10.1016\/j.chroma.2020.461767_bib0038","unstructured":"Optimization in Drug Discovery - In Vitro Methods | Gary W. Caldwell | Springer, (n.d.). https:\/\/www.springer.com\/gp\/book\/9781627037419 (accessed July 18, 2020)."},{"key":"10.1016\/j.chroma.2020.461767_bib0039","doi-asserted-by":"crossref","unstructured":"Red Blood Cells: A Neglected Compartment in Pharmacokinetics and Pharmacodynamics | Pharmacological Reviews, (n.d.). http:\/\/pharmrev.aspetjournals.org\/content\/49\/3\/279 (accessed July 18, 2020).","DOI":"10.1016\/S0031-6997(24)01329-2"},{"key":"10.1016\/j.chroma.2020.461767_bib0040","article-title":"Separation and characterization of red blood cells with different membrane deformability using steric field-flow fractionation","volume":"674","author":"X","year":"1995","journal-title":"Journal of Chromatography. B, Biomedical Applications"},{"key":"10.1016\/j.chroma.2020.461767_bib0041","unstructured":"Separation of red blood cells by field flow fractionation. - Abstract - Europe PMC, (n.d.). https:\/\/europepmc.org\/article\/med\/8425568 (accessed July 18, 2020)."},{"key":"10.1016\/j.chroma.2020.461767_bib0042","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1006\/abio.1993.1287","article-title":"Separation and Size Distribution of Red Blood Cells of Diverse Size, Shape, and Origin by Flow\/Hyperlayer Field-Flow Fractionation","volume":"212","year":"1993","journal-title":"Analytical Biochemistry"},{"key":"10.1016\/j.chroma.2020.461767_bib0043","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/3-540-48764-6_2","article-title":"Field-Flow Fractionation Techniques for Polymer and Colloid Analysis","author":"C\u00f6lfen","year":"2000","journal-title":"New Developments in Polymer Analytics I"}],"container-title":["Journal of Chromatography A"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021967320310414?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021967320310414?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T06:03:16Z","timestamp":1758261796000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021967320310414"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":43,"alternative-id":["S0021967320310414"],"URL":"https:\/\/doi.org\/10.1016\/j.chroma.2020.461767","relation":{},"ISSN":["0021-9673"],"issn-type":[{"value":"0021-9673","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Asymmetric-flow field-flow fractionation for measuring particle size, drug loading and (in)stability of nanopharmaceuticals. The joint view of European Union Nanomedicine Characterization Laboratory and National Cancer Institute - Nanotechnology Characterization Laboratory","name":"articletitle","label":"Article Title"},{"value":"Journal of Chromatography A","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chroma.2020.461767","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"461767"}}